Market Place
Sourcing Support
Arrowhead Pharma Unveils Plozasiran Data On Hypertriglyceridemia
28 Mar 2026 //
PHARMIWEB
Sarepta Overcomes Gene Therapy Setback With Early RNA Therapy
26 Mar 2026 //
BIOSPACE
Sarepta`s Big Bet On Arrowhead`s Sirna Assets Yields Early Data
25 Mar 2026 //
FIERCE BIOTECH
Revolution, Ascendis Seen As Top Buyout Targets In Biopharma
19 Mar 2026 //
BIOSPACE
Arrowhead Pharma Starts Phase 1/2A Trial For ARO-DIMER-PA
27 Jan 2026 //
BUSINESSWIRE
Arrowhead Pharma Reports Weight Loss in Obesity RNAi Trial
06 Jan 2026 //
BUSINESSWIRE
Arrowhead Pharma Launches Phase 1/2a ARO-MAPT Trial in
08 Dec 2025 //
BUSINESSWIRE
Arrowhead Pharma Granted Breakthrough Designation For Plozasiran
02 Dec 2025 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results
25 Nov 2025 //
BUSINESSWIRE
Arrowhead Pharma Receives $200M Milestone Payment From Sarepta
24 Nov 2025 //
BUSINESSWIRE
Arrowhead Files CTA For ARO-DIMER-PA In Mixed Hyperlipidemia
07 Oct 2025 //
PHARMIWEB
Ionis, Arrowhead in Patent Lawsuits Over Genetic Disorder Drug
11 Sep 2025 //
REUTERS
Arrowhead Seeks Clearance for Ph 1/2a ARO-MAPT Alzheimer`s Study
10 Sep 2025 //
PHARMAWEB
Arrowhead, Novartis in Up to $2B Deal for Neuromuscular Therapy
03 Sep 2025 //
REUTERS
Sarepta Sells 9M Arrowhead Shares for $174M
13 Aug 2025 //
FIERCE BIOTECH
Arrowhead Redeems $50M Stock, Gets $50M Sarepta Milestone
13 Aug 2025 //
BUSINESSWIRE
Sarepta Advances siRNA Collaboration, Sells Arrowhead Equity
13 Aug 2025 //
BUSINESSWIRE
Arrowhead Emerges as RNAi Knight Amid Sarepta `Downdraft`
12 Aug 2025 //
BIOSPACE
Sanofi pens $395M China pact for Arrowhead Metabolic med
02 Aug 2025 //
PRESS RELEASE
Arrowhead Hits $100M Milestone, Awaits Sarepta Payment
28 Jul 2025 //
FIERCE BIOTECH
Arrowhead Reassures investors about pact with troubled Sarepta
24 Jul 2025 //
PRESS RELEASE
Arrowhead Starts Phase 3 YOSEMITE Study of Zodasiran
08 Jul 2025 //
BUSINESSWIRE
Arrowhead Completes Enrollment in Three Plozasiran Trials
23 Jun 2025 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Begins Study of ARO-ALK7 for Obesity
02 Jun 2025 //
BUSINESSWIRE
Arrowhead Reports Topline Ph1/2 ARO-C3 Data In IgA Nephropathy
10 Mar 2025 //
BUSINESSWIRE
Arrowhead Showcases 2RNAi Candidates For Obesity, Metabolic Disease
06 Mar 2025 //
BUSINESSWIRE
Arrowhead`s Preclinical Data On ARO-ALK7 For Obesity Treatment
25 Feb 2025 //
BUSINESSWIRE
Arrowhead`s NDA For Plozasiran Accepted By FDA For Chylomicronemia
17 Jan 2025 //
BUSINESSWIRE
Arrowhead Presents Interim ARO-CFB Data For Complement Diseases
11 Dec 2024 //
BUSINESSWIRE
Sarepta, Arrowhead ink $1B-plus deal for seven programs
27 Nov 2024 //
FIERCE BIOTECH
Arrowhead Presents New Plozasiran Data at AHA24 & Studies
18 Nov 2024 //
BUSINESSWIRE
Arrowhead Submits NDA for Plozasiran in Familial Chylomicronemia
18 Nov 2024 //
BUSINESSWIRE
Arrowhead Files For ARO-INHBE Phase 1/2a Obesity Study
23 Sep 2024 //
BUSINESSWIRE
Arrowhead`s Plozasiran Gets FDA Breakthrough Designation
10 Sep 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Advances Plozasiran to Phase 3 CAPITAN Trial
25 Jun 2024 //
BUSINESSWIRE
Arrowhead`s Plozasiran Successful Topline Familial Chylomicronemia Data
03 Jun 2024 //
BUSINESSWIRE
Arrowhead: New Phase 2 Plozasiran Data In Mixed Hyperlipidemia Patients
28 May 2024 //
BUSINESSWIRE
Arrowhead Presents ARO-RAGE High Gene Knockdown In Asthma
20 May 2024 //
BUSINESSWIRE
Arrowhead Initiates ARO-CFB Kidney Disease Study
24 Apr 2024 //
BUSINESSWIRE
Arrowhead Announces Ph 2 Data of Plozasiran Published in JAMA Cardiology
07 Apr 2024 //
BUSINESSWIRE
Arrowhead Initiates Program for Plozasiran and Announces Upcoming Presentation
25 Mar 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1
08 Mar 2024 //
BUSINESSWIRE
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB
21 Dec 2023 //
BUSINESSWIRE
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1
28 Nov 2023 //
BUSINESSWIRE
Arrowhead Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023
13 Nov 2023 //
BUSINESSWIRE
Arrowhead Files for Regulatory Clearance to Initiate a Ph 1/2 Study of ARO-DUX4
17 Jul 2023 //
BUSINESSWIRE
Arrowhead Files for Regulatory Clearance to Initiate a Ph1 Study of ARO-SOD1
27 Jun 2023 //
BUSINESSWIRE
Arrowhead Presents Updated Data from Ph2 SEQUOIA Study RNAi Therapy Fazirsiran
24 Jun 2023 //
BUSINESSWIRE
Arrowhead Presents Interim Data from ARO-ANG3 Phase 2 GATEWAY Study
23 May 2023 //
BUSINESSWIRE
ADC biotech brings total Series A raise to $89M+; Takeda hands $40M to Arrowhead
04 Apr 2023 //
ENDPTS
Arrowhead Receives FDA Fast Track Designation for ARO-APOC3
20 Mar 2023 //
BUSINESSWIRE
Arrowhead Initiates Ph1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis
02 Feb 2023 //
BUSINESSWIRE
Takeda, Arrowhead tout Phase II data for fazirsiran in alpha-1 liver disease
10 Jan 2023 //
PRESS RELEASE
Arrowhead and Takeda Announce Results from SEQUOIA Phase 2 Study of Fazirsiran
09 Jan 2023 //
BUSINESSWIRE
